Mark Anthony McCamish - Jul 30, 2024 Form 4 Insider Report for AVADEL PHARMACEUTICALS PLC (AVDL)

Role: Director
Signature: /s/ Jerad G. Seurer, as Attorney-in-Fact
Stock symbol: AVDL
Transactions as of: Jul 30, 2024
Transactions value $: $0
Form type: 4
Date filed: 8/1/2024, 04:32 PM
Previous filing: Jan 8, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AVDL	Ordinary Shares	Award	$0	+11K		$0.00	11K	Jul 30, 2024	Direct	F1
holding	AVDL	Ordinary Shares						67K	Jul 30, 2024	By Matthew 5 LLC	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVDL	Stock Option (Right to Buy)	Award	$0	+11K		$0.00	11K	Jul 30, 2024	Ordinary Shares	11K	$16.32	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted share units ("RSUs"). Each RSU represents the contingent right to receive one Ordinary Share upon vesting and settlement. The RSUs shall vest in full on the earlier to occur of (a) July 30, 2025 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time.
F2	Shares held by Matthew 5 LLC. The Mark & Barbara McCamish Family Trust is the sole owner of Matthew 5 LLC, and the Reporting Person serves as its manager.
F3	The options shall vest in full on the earlier to occur of (a) July 30, 2025 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time.